COMPOSITIONS AND METHODS FOR LOCALIZED THERAPY OF THE EYE
    21.
    发明申请
    COMPOSITIONS AND METHODS FOR LOCALIZED THERAPY OF THE EYE 审中-公开
    眼睛局部治疗的组合物和方法

    公开(公告)号:US20120142652A1

    公开(公告)日:2012-06-07

    申请号:US13367070

    申请日:2012-02-06

    IPC分类号: A61K31/58 A61P27/02 B82Y5/00

    摘要: Compositions, and methods of using such compositions, useful for injection into the posterior segments of human or animal eyes are provided. Such compositions include small particles of a poorly soluble therapeutic agent that facilitates formation of concentrated regions of the therapeutic agent in the retinal pigmented epithelium of an eye. The particles are formed by combining a therapeutic agent with an ophthalmically acceptable polymer component. The particles have sizes less than about 3000 nanometers, and in some cases, less than about 200 nanometers. One example of composition includes particles of triamcinolone acetonide and hyaluronic acid have a size less than about 3000 nanometers.

    摘要翻译: 提供了组合物和使用这种组合物的方法,其可用于注射到人或动物眼睛的后段中。 这样的组合物包括促进在眼睛的视网膜色素上皮中形成治疗剂的浓缩区域的难溶性治疗剂的小颗粒。 通过将治疗剂与眼科可接受的聚合物组分组合来形成颗粒。 颗粒具有小于约3000纳米的尺寸,并且在一些情况下小于约200纳米。 组合物的一个实例包括曲安奈德的颗粒和透明质酸的尺寸小于约3000纳米。

    METHODS AND COMPOSITIONS FOR INTRAOCULAR ADMINISTRATION TO TREAT OCULAR CONDITIONS
    26.
    发明申请
    METHODS AND COMPOSITIONS FOR INTRAOCULAR ADMINISTRATION TO TREAT OCULAR CONDITIONS 有权
    用于治疗眼睛条件的室间管理的方法和组合

    公开(公告)号:US20080241252A1

    公开(公告)日:2008-10-02

    申请号:US11695527

    申请日:2007-04-02

    IPC分类号: A61K9/14 A61K31/33

    摘要: Anti-angiogenesis compositions, and methods of using such compositions, useful for injection into the vitreous of human eyes are provided. Such compositions can include TKI component solutions or particles present in a therapeutically effective amount, a viscosity inducing component, and an aqueous carrier component. The compositions have viscosities at about 25° C. of at least about 10 cps or about 100 cps at a shear rate of 0.1/second. In a preferred embodiment, the viscosity at 25° C. is in the range of from about 80,000 cps to about 300,000 cps.

    摘要翻译: 提供了抗血管生成组合物,以及使用这些组合物的方法,其可用于注射到人眼玻璃体中。 这样的组合物可以包括TKI组分溶液或以治疗有效量存在的颗粒,粘度诱导组分和水性载体组分。 组合物在约25℃下的粘度为0.1 /秒的剪切速率为至少约10cps或约100cps。 在优选的实施方案中,25℃下的粘度在约80,000cps至约300,000cps的范围内。

    Peripherally administered viscous formulations
    29.
    发明授权
    Peripherally administered viscous formulations 有权
    外周施用的粘稠制剂

    公开(公告)号:US08846094B2

    公开(公告)日:2014-09-30

    申请号:US11828561

    申请日:2007-07-26

    摘要: Viscous formulations and methods of using such compositions, useful for intramuscular and intra-articular injection are provided to treat peripheral conditions. Such compositions can include triamcinolone particles present in a therapeutically effective amount, a viscosity inducing component, and an aqueous carrier component. The compositions have viscosities of at least about 10 cps or about 100 cps at a shear rate of 0.1/second. In a preferred embodiment, the viscosity is in the range of from about 80,000 cps to about 300,000 cps. In a most preferred embodiment, the viscosity is in the range of from about 140,000 cps to about 280,000 cps at a shear rate of 0.1/second at 25° C. The compositions advantageously suspend the triamcinolone particles for prolonged periods of time.

    摘要翻译: 提供使用这种组合物的粘性制剂和方法,其可用于肌肉内和关节内注射以治疗外周病症。 这样的组合物可以包括以治疗有效量存在的曲安奈德颗粒,粘度诱导组分和水性载体组分。 组合物在0.1 /秒的剪切速率下具有至少约10cps或约100cps的粘度。 在优选的实施方案中,粘度在约80,000cps至约300,000cps的范围内。 在最优选的实施方案中,粘度在25℃下以0.1 /秒的剪切速率在约140,000cps至约280,000cps的范围内。组合物有利地将曲安奈德颗粒悬浮较长时间。